Hariparsad N, 1273
Harmatz JS, 605
Hartford A, 487, 1054
Harvey AT, 1173
Hashem M, 1328
Haskell LP, 621
Hayes MJ, 158
He W, 1054
Hebert MF, 89
Heinpalu M, 1143
Henkel T, 590
Heo YS, 1166
Hermann R, 510
Hermida J, 974
Herron J, 1252
Hewitt RG, 293
Hichwa RD, 751
Hirano T, 481
Hochhaus G, 510
Hoelscher D, 689
Hoffer C, 224
Hogerzeil HV, 1106
Holdbrook F, 981
Holloway K, 1106
Hossain M, 599
Howell SR, 379
Hu P, 1260
Huang M, 1023
Huang S-M, 559
Hubbard RC, 474
Hughes D, 680
Hunt T, 532
Hunt TL, 83, 503
Hutin YJF, 1106
Huynh P, 7
Iacono A, 135
Imai H, 95
Ishkanian G, 1158
Itoh M, 890
Iwabuchi K, 890
Iwata R, 890
Jabbour JT, 359
Jacobs L-D, 1282
Jacobsen LV, 258
Jamali F, 245
Jang I-J, 73
Jeha S, 1309
Jenkins PL, 696
Jensen BK, 348, 901
Jhee SS, 258
Jiang H, 1260
Jiang J, 1260
Jiang T, 1323
Jiwatani S, 723
Jodynis-Liebert J, 338
Johansson S, 388
Johnson JA, 1083
Johnson M, 1301
Jusko WJ, 991, 1034
Juszczyk J, 338
Kadota R, 1309
Kalbag J, 646
Kalies I, 928
Kamal MA, 1034
Kaneda A, 538
Kaneko S, 538
Kang Y-K, 1166
Kantesaria B, 1252
Karyekar CS, 919
Kashuba ADM, 570, 708
Katneni K, 723
Kato M, 890
Katzper M, 368
Kays MB, 1012
Kazierad DJ, 457
Kearns GL, 487
Keefe DL, 679
Kennedy MJ, 708
Kessler E, 388, 935
Khalil MH, 1132
Kharasch ED, 224
Khetani VD, 173
Kim JS, 570
Kim K, 1083
Kim M-J, 570, 696, 966
Kim SB, 1166
Kim SC, 743
Kim TW, 1166
Kim WK, 1166
Kinchelow T, 793
Kink-Eiband M, 777
Kirkesseli S, 348
Kitt M, 689
Kleiman NS, 981
Kline WF, 48
Knebel W, 590
Knorr B, 487
Koeppel J, 751
Kolis S, 793
Korth-Bradley J, 543, 873, 1244
Kotegawa T, 95
Kovarik JM, 532
Kowey PR, 1063
Kraft WK, 67, 305, 1125
Krause D, 590
Krauwinkel WJ, 1023
Kuritsch I, 777
Kusma SE, 305
Kutz K, 59
Kuzmak B, 373
Lai A, 253
Lai AA, 83, 503
LaLonde T, 1328
Lam GN, 1309
Lamba J, 135
Larson AM, 89
Lasseter KC, 1054
Lau DTW, 495
Laurent A, 193
LaVallee N, 510
Le Coz F, 1244
Leclerc V, 234
Lee D, 767
Lee JS, 1166
Lee L, 599
Lee SSCL, 632
Lee Y, 215
Leeder JS, 708
Leese P, 646
Lefebvre M, 640
Lehmann D, 861
Lehtonen L, 1143
Leibowitz MT, 258
Lensing P, 837
Leroy B, 234
Lesko LJ, 559
Levy RH, 1230
Lew RA, 457
Lewanczuk RZ, 245
Li Q, 577
Li W-B, 785
Li Z, 577
Lim H-S, 73
Lin C-C, 265
Linke R, 866
Liu J, 577
Liu L, 1054
Ljungqvist A, 293
Lloyd P, 158
Locher M, 510
Logez SMD, 1106
Loogna I, 1143
Lou Y, 1301
Lowry R, 305
Lu J, 1260
Ludden T, 590
Lyness WH, 258
Ma JD, 447, 570
Ma T, 767
Maglio D, 188
Majumdar AK, 215
Mallikaarjun S, 179
Mamidi RNVS, 723
Mann J, 59
Marbury T, 234
Marbury TC, 48
Markabi S, 1290
Martin D, 1151
Martin LL, 379, 901
Martin NE, 379, 621, 901
Massicotte J, 640
Mathijssen RHJ, 854
Matthews CZ, 48, 1125
Matuszewska A, 338
Mayer PR, 873, 1235
Mayersohn M, 1151
Mazenko RS, 48, 1125
McCrea JB, 305
McCurry K, 135
McDade K, 135
McLeod JF, 120
Mehendale SR, 1323
Mehring G, 158
Menchaca D, 495
Metzger D, 543
Meyerrose GE, 150
Michael J, 1328
Michiels N, 1125
Mignot A, 1114
Migoya E, 487
Miller JL, 1125
Millerioux L, 1114
Milosavljev S, 193, 646
Minton N, 991
Miyaoka M, 481
Mochizuki H, 890
Moncrief JW, 48
Montay G, 234
Moon B-S, 73
Morganroth J, 689
Morimoto T, 95
Moriyasu F, 481
Moser L, 1328
Motte J, 1290
Mottern RK, 359
Mudaliar S, 414
Murdoch RD, 1046
Murphy G, 1054
Nafziger AN, 447, 570, 696, 966
Nakano S, 95
Nallani SC, 1273
Natarajan J, 464
Nave R, 37
Nelsen J, 861
Neumayer H-H, 163
Newman N, 861
Nicolau DP, 188
Noel GJ, 464
Noveck RJ, 474
Obach RS, 7
Oertel R, 1282
Oh JM, 743
Ohlsson L, 928
Ohtani Y, 95
Oka K, 481
Okerholm RA, 253
O'Leary DS, 751
Onda K, 481
Overholser BR, 1012
Padmanabhan M, 464
Pairet M, 777

Palic B, 293
Pan W-J, 1230
Paolini JF, 1054
Paoluzzi L, 854
Parchman LG, 981
Parisi S, 520
Park JM, 89
Parks V, 543, 1244
Patat A, 543, 1244
Patel IH, 793
Peng B, 158
Petty KJ, 48, 215
Pfister M, 621
Philips L, 265
Pistner H, 1282
Planken Ü, 1143
Plunkett W, 1309
Põder P, 1143
Pokorny R, 158
Pollak PT, 141
Pons G, 1290
Ponto LLB, 751
Pope LE, 1132
Porras AG, 48, 1125
Preskorn SH, 1173
Price DK, 854
Prisant LM, 394, 406, 423
Prueksaritanont T, 1054
Putcha L, 837
Qiu Y, 1054
Quiring JN, 67
Ragueneau-Majlessi I, 1230
Rajman I, 457
Ramakrishnan R, 991
Ramananth V, 861
Randall S, 1301
Rantanen S, 1143
Razzouk B, 1309
Reed KA, 1003
Reed RC, 737
Rehan A, 1328
Rey E, 1290
Richmond JCW, 751
Richter K, 1282
Ristich J, 135
Riviere G-J, 532
Robson RA, 48
Rodríguez CA, 276
Rohatagi S, 37, 348
Rojas PB, 258
Romanelli M, 1328
Rominger K-L, 163
Rordorf C, 193, 646
Roscigno R, 83, 503
Rosenfeld W, 1230
Roset PN, 30
Rosman HS, 1328
Rowland E, 570
Roze J-C, 1114
Russell A, 245
Russo R, 188
Ruxrungtham K, 793
Rytting M, 1309
Ryu M-H, 1166
Sack M, 234
Sack MR, 48
Saito M, 1223
Sakurada Y, 890
Salazar DE, 179
Sane RS, 1273
Sarich TC, 388, 935, 1063
Sarich TS, 928
Sattler G, 1282
Scavone JM, 605
Scharf MB, 253
Scheffler MR, 173
Schinzel S, 1282
Schmerler M, 1230
Schmitt BA, 751
Schmouder R, 532
Schofield JP, 1046
Schreiber TL, 1328
Schuck EL, 837
Schuetz E, 135
Schultz A, 1125
Schur JL, 293
Schützer K-M, 388, 928, 935, 1063
Schwartz JI, 48
Scott G, 193, 646
Sedek G, 599
Seiberling M, 158
Sekiguchi K, 284
Sellers EM, 966, 1132
Shader RI, 605
Shadle CR, 215
Shafer SL, 141
Shah A, 520
Shah B, 348
Shah J, 1230
Shang Y, 881
Shelton MJ, 293
Shi J, 234
Shimatani K, 284
Shin S-G, 73
Shon J-H, 73
Shoyama Y, 1323
Siebert-Weigel M, 510
Sigmund R, 163
Simcoe D, 1244
Singh AS, 854
Slowinski T, 163
Smith A, 861
Smith J, 150
Smulders RA, 1023
Soares-da-Silva P, 906
Sobue S, 284
Solanki B, 464
Song K-S, 73
Sowers JR, 397
Sowinski KM, 1012
Sparreboom A, 854
Spénard J, 640
Spencer E, 689
Srinivas ML, 723
Srinivas NR, 115, 723
Staton BA, 276
Steiger B, 67
Stein DS, 1301
Steinherz P, 1309
Stiles M, 1132
Stirling DI, 173
Stogniew M, 590
Stoltz R, 520
Sturm Y, 1290
Stypinski D, 173
Suarez JA, 150
Subramaniam S, 723
Sugawara K, 1223
Sundberg S, 1143
Surath A, 723
Swan S, 48
Swan SK, 234
Swart PJ, 1023
Szefler S, 37
Takahata T, 1223
Tan K, 284
Tang ZR, 577
Tashiro M, 890
Tateishi T, 538, 1223
Tay LK, 680
Teng R, 388, 1063
Teo SK, 173
Terra SG, 457
Thomas SD, 173
Thompson GA, 373
Thon A, 866
Toma T, 481
Tomlinson B, 582
Tong Z, 120
Tornatore KM, 1003
Tozzi CA, 487
Tran A, 1290
Tremblay C, 640
Trummlitz G, 777
Tsikouris JP, 150, 327
Tsutsumi K, 95
Tuerck D, 866
Türck D, 163
Tutor JC, 974
Tutor-Crespo MJ, 974
Uno T, 1223
Uppalapati S, 723
Upreti VV, 723
Valdez J, 1151
Valesky R, 1054
van Adelsberg J, 487
van Ryn J, 777
Vargas R, 234
Vega JM, 1054
Venkataramanan R, 743
Venuto RC, 1003
Verweij J, 854
von Moltke LL, 679
Wacholtz MC, 991
Wade A, 1158
Wade M, 83, 503
Wajdula J, 1235
Waldman SA, 67, 305, 1125
Wall U, 388, 928, 935
Wallenstein G, 777
Wang C-Y, 785, 1323
Wang D, 577
Wang L-S, 577
Wang X, 881
Wang Y, 532, 599, 646
Ward CA, 751
Watkins GL, 751
Waye MMY, 582
Webber DM, 1046
Webber S, 135
Weber W, 163
Wehling M, 1125
Wei GC, 457
Weitman S, 1309
Weng Y-Z, 785
Werder S, 1173
Whitaker A-M, 188
Whittington D, 224
Winchell GA, 305
Winer N, 397
Wollbratt M, 935
Wong DF, 890
Wong PH, 48
Wong SL, 495
Woolf EJ, 48, 305, 1125
Worley DJ, 373
Worth E, 951
Wu A, 173
Wu J, 577
Xu C, 265
Yakatan GJ, 1132
Yamasaki H, 1328
Yanai K, 890
Yasui-Furukori N, 538, 1223
Yeh C-M, 193
Yeh L-T, 265
Yi S-Y, 73
Yih L, 193
Yin OQP, 582
Yu K-S, 73
Yuan C-S, 1323
Zaldonis D, 135

Zarotsky V, 258
Zech K, 37
Zeevi A, 135
Zeng Z, 348
Zhai Y-M, 785
Zhang J, 135, 348
Zhang X, 793
Zhang Y, 966
Zhang Z-J, 785
Zhao J, 487
Zhao JJ, 1054
Zhao J-P, 785
Zheng H, 135
Zhou G, 577
Zhou H, 120, 543, 1235, 1244
Zhou H-H, 577, 785
Zhou YS, 680
Zhu B, 577
Zhu J, 881
Zhu R-H, 785
Ziska M, 150
Zussman B, 1046

Subject Index, Volume 44 (2004)

Abarelix

pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75, 495

Absolute bioavailability

absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion, 83

Absorption

absorption of rivastigmine from different regions of the gastrointestinal tract in humans, 599

ACE inhibitor

blood pressure control and nephroprotection in diabetes, 431

optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240, 621

pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901

pharmacological and clinical profile of moexipril: a concise review, 827

questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? 150

ACE/NEP inhibitor

effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 1380

no clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 379

Adolescents

pharmacokinetics of frovatriptan in adolescent migraineurs, 1158

Adverse effects

hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, 1166

intramuscular haloperidol or lorazepam and QT intervals in schizophrenia, 1173

Alcohol

the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol, 388

Aldehyde oxidase

human liver aldehyde oxidase: inhibition by 239 drugs, 7

Alzheimer's disease

the effects of *Ginkgo biloba* extracts on the pharmacokinetics and pharmacodynamics of donepezil, 538

American College of Clinical Pharmacology

annual meeting abstract, 1185

Aminoglycoside-associated nephrotoxicity

application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing, 696

Amiodarone

a pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor, 1063

Amprenavir

pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1–infected children, 1301

Analgesia

analgesic effect of sustained-release flurbiprofen administered at the site of tissue injury in the oral surgery model, 1419

assessment of visual analog versus categorical scale for measurement of osteoarthritis pain, 368

effect of modafinil on acute pain: a randomized double-blind crossover study, 1426

efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty, 767

Angelicae dahuricae

effects of *Corydalis yanhusuo* and *Angelicae dahuricae* cold pressor–induced pain in humans: a controlled trial, 1323

Angiotensin II

pharmacological and clinical profile of moexipril: a concise review, 827

Angiotensin II type 1 receptor

rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan, 245

Anidulafungin

population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, 590

Anti-inflammatory drugs

analgesic effect of sustained-release flurbiprofen administered at the site of tissue injury in the oral surgery model, 1419

Antibacterial

effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects, 689

Anticoagulants

the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol, 388

possible induction of cholinesterase in epileptic patients treated with anticonvulsant drugs: relationship with lipoprotein levels, 974

safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans, 906

Antidepressives

DOV 216,303, "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile, 1361

Antiemetic agents

pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects, 520

Antifungal

pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers, 284

population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, 590

Antiplatelet

intense management of diabetes mellitus: role of glucose control and antiplatelet agents, 414

meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers, 777

Antiretrovirals

indinavir and rifabutin drug interactions in healthy volunteers, 305

Aprepitant

evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity, 215

Argatroban

pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention, 981

Aripiprazole

pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers, 179

Arthritis

assessment of visual analog versus categorical scale for measurement of osteoarthritis pain, 368

pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis, 866

Arthroplasty

efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty, 767

Articane hydrochloride

pharmacokinetics of articane hydrochloride in tumescent local anesthesia for liposuction, 1282

Aspirin

meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers, 777

Asthma

pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old, 487

the pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers, 6

pharmacokinetics, safety, and tolerability of R411, a dual α4β1-α4β7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers, 1369

risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective, 37

Atorvastatin

no pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran, 928

Atropisomer

simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist, 680

Attention deficit hyperactivity disorder

a single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects, 173

Azimilide

influence of azimilide on CYP2C19-mediated metabolism, 373

Bayes theorem

application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing, 696

BIA 2-093

safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans, 906

Bioavailability

absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion, 158

influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline, 640

Bioequivalence

role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus? 115

Bismuth biskalcitrate

influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline, 640

Blood pressure measurements

evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials, 457

Breast cancer

lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition, 861

Breastfeeding

characterization of the penetration of garenoxacin into the breast milk of lactating women, 188

BSM-207940

simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist, 680

Caffeine

comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children, 708

serum metabolite/caffeine ratios as a test for liver function, 338

Camphor

dermal absorption of camphor, menthol, and methyl salicylate in humans, 1151

Camptothecin

safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study, 723

Cancer

pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia, 873

safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study, 723

Capecitabine

hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, 1166

Cardiac repolarization

effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects, 689

Cardiovascular disease

benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong, 632

epidemiology of diabetes, 397

Cardiovascular function

effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [^{15}O]water: effect in occasional and chronic users, 751

Cephalexin

randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate, 1392

Cetirizine

central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H_1-receptor occupancy using ^{11}C-doxepin positron emission tomography, 890

Chiral

role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus? 115

Cholinesterase

possible induction of cholinesterase in epileptic patients treated with anticonvulsant drugs: relationship with lipoprotein levels, 974

Chronic obstructive pulmonary disease

pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment, 163

Cilomilast

lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers, 1046

Cimetidine

renal interaction between itraconazole and cimetidine, 919

Ciprofloxacin

sex-related differences in the pharmacokinetics of oral ciprofloxacin, 1012

Cisplatin

hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, 1166

Citalopram

utility of sparse concentration sampling for citalopram in elderly clinical trial subjects, 1353

Clinical studies

application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing, 696

effects of nicotine on the number and activity of circulating endothelial progenitor cells, 881

possible induction of cholinesterase in epileptic patients treated with anticonvulsant drugs: relationship with lipoprotein levels, 974

questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? 150

Clinical trials

evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials, 457

parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters, 474

Clofarabine

population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia, 1309

Clozapine

the differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers, 785

teaching application of clinical pharmacology skills using unusual observations from clozapine overdoses, 141

"Cocktail"

"cocktail" approaches and strategies in drug development: valuable tool or flawed science? 120

Colitis

MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration, 481

Congestive heart failure

pharmacokinetics and pharmacodynamics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study, 1143

Contraceptives

concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile, 646

Coronary artery disease

effects of nicotine on the number and activity of circulating endothelial progenitor cells, 881

Corydalis yanhusuo

effects of *Corydalis yanhusuo* and *Angelicae dahuricae* cold pressor–induced pain in humans: a controlled trial, 1323

COX-1

meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers, 777

COX-2

pharmacokinetics of etoricoxib in patients with renal impairment, 48

COX-2 inhibitor

lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects, 193

parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters, 474

Cyclooxygenase

the effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity, 1125

pharmacokinetics of etoricoxib in patients with renal impairment, 48

CYP

"cocktail" approaches and strategies in drug development: valuable tool or flawed science? 120

lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition, 861

CYP2C9

evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity, 215

limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers, 570

CYP2C19

effects of lansoparole pharmacokinetics in relation to CYP2C19 genotypes, 1223

influence of azimilide on CYP2C19-mediated metabolism, 373

influence of St. John's wort on CYP2C19 activity with respect to genotype, 577

lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping, 966

omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability, 582

CYP2D6

assessment of in vivo CYP2D6 activity: differential sensitivity on commonly used probes to urine pH, XXX

CYP3A

the effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity, 1125

interindividual and intraindividual variability of the urinary 6β-hydroxycortisol/cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity, 1413

no clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 379

CYP3A4

evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity, 215

induction of CYP3A4 be efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital, 1273

CYP3A5

tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, 135

Cytochrome P450 enzymes

genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers, 447

Daptomycin

moderate liver impairment has no influence on daptomycin pharmacokinetics, 715

single-dose pharmacokinetics of daptomycin in young and geriatric volunteers, 612

Depression

effects of St. John's wort (*Hypericum perforatum*) on tacrolimus pharmacokinetics in healthy volunteers, 89

utility of sparse concentration sampling for citalopram in elderly clinical trial subjects, 1353

Dermal patches

dermal absorption of camphor, menthol, and methyl salicylate in humans, 1151

Desloratadine

pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers, 1252

Dexmethylphenidate HCl

a single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects, 173

Dextromethorphan

comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children, 708

pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers, 1132

Dextrorphan

pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers, 1132

Diabetes

blood pressure control and nephroprotection in diabetes, 431

clinical trials and lipid guidelines for type II diabetes, 423

diabetes mellitus: an imperative for prevention and intense management, 394

epidemiology of diabetes, 397

intense management of diabetes mellitus: role of glucose control and antiplatelet agents, 414

preventing type II diabetes mellitus, 406

Digoxin

absence of a clinically relevant interaction between etanercept and digoxin, 1244

no pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers, 935

Dihydrouracil

important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics, 1260

Docetaxel

hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, 1166

Donepezil

the effects of *Ginkgo biloba* extracts on the pharmacokinetics and pharmacodynamics of donepezil, 538

Dopamine

dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy, 1343

DOV 216,303

DOV 216,303, "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile, 1361

DRF-1042

safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study, 723

Drug development

drug-drug, drug–dietary supplement, and drug–citrus fruit and other food interactions: what have we learned? 559

effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects, 689

role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus? 115

simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist, 680

Drug-dietary supplement

drug-drug, drug–dietary supplement, and drug–citrus fruit and other food interactions: what have we learned? 559

Drug-drug interaction

"cocktail" approaches and strategies in drug development: valuable tool or flawed science? 120

drug-drug, drug–dietary supplement, and drug–citrus fruit and other food interactions: what have we learned? 559

lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients, 793

no clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 379

Drug-herb interactions

the effects of *Ginkgo biloba* extracts on the pharmacokinetics and pharmacodynamics of donepezil, 538

Drug interactions

absence of a pharmacokinetic interaction between etanercept and warfarin, 543

concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile, 646

the differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers, 785

dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia, 1386

effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers, 95

the effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone, 293

effects of St. John's wort (*Hypericum perforatum*) on tacrolimus pharmacokinetics in healthy volunteers, 89

human liver aldehyde oxidase: inhibition by 239 drugs, 7

ibandronate: a clinical pharmacological and pharmacokinetic update, 951

indinavir and rifabutin drug interactions in healthy volunteers, 305

influence of azimilide on CYP2C19-mediated metabolism, 373

influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline, 640

influence of St. John's wort on CYP2C19 activity with respect to genotype, 577

interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays, 1034

lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients, 793

lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers, 1046

lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects, 193

meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers, 777

metabolism by n-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition, 1406

no pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran, 928

no pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers, 935

parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters, 474

a pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor, 1063

the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol, 388

randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate, 1392

renal interaction between itraconazole and cimetidine, 919

simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans, 1054

Drug metabolism

"cocktail" approaches and strategies in drug development: valuable tool or flawed science? 120

comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children, 708

effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers, 95

the effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity, 1125

evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity, 215

genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers, 447

human liver aldehyde oxidase: inhibition by 239 drugs, 7

influence of azimilide on CYP2C19-mediated metabolism, 373

interindividual and intraindividual variability of the urinary 6β-hydroxycortisol/cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity, 1413

limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers, 570

metabolism by n-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition, 1406

no clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 379

pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers, 1132

quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl, 224

tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, 135

Drug policy

could the WHO model list of essential medicines do more for the safe and appropriate use of injections? 1106

Drug safety

pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers, 179

pharmacokinetics and safety of solifenacin succinate in healthy young men, 1023

ECG readings

measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings, 464

Education

benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong, 632

putting clinical pharmacology in context: the use of popular movies, 30

teaching application of clinical pharmacology skills using unusual observations from clozapine overdoses, 141

Efavirenz

induction of CYP3A4 be efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital, 1273

Electroencephalography

kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions, 605

Endogenous cortisol
intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects of endogenous cortisol, 510

Endothelia progenitor cells
effects of nicotine on the number and activity of circulating endothelial progenitor cells, 881

Endothelin receptor
pharmacokinetics and pharmacodynamics of the ET_A-selective endothelin receptor antagonist SPP301 in healthy human subjects, 59
simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist, 680

Enfuvirtide
lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients, 793

Epilepsy
lack of a clinically significant effect of zonisamide on phentyoin steady-state pharmacokinetics in patients with epilepsy, 1230
oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy, 1290
safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans, 906

Erythromycin breath test
the effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity, 1125

Erythropoietin
pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers, 991

Estrogen receptor
lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition, 861

ET_A-selective endothelin receptor antagonist
pharmacokinetics and pharmacodynamics of the ET_A-selective endothelin receptor antagonist SPP301 in healthy human subjects, 59

Etanercept
absence of a clinically relevant interaction between etanercept and digoxin, 1244
absence of a pharmacokinetic interaction between etanercept and warfarin, 543
unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid athritis, 1235

Etoricoxib
the effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity, 1125
pharmacokinetics of etoricoxib in patients with renal impairment, 48

Extended-interval dosing
application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing, 696

Fenofibrate
simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans, 1054

Fenoldopam
dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy, 1343

Fentanyl
quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl, 224

Fexofenadine
central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H_1-receptor occupancy using ^{11}C-doxepin positron emission tomography, 890

5-HT3 receptor antagonist
pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects, 520

Fluconazole
lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects, 193
pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers, 284

Fluoropyrimidine
important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics, 1260

Fluoxetine
pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers, 1252

Flurbiprofen
analgesic effect of sustained-release flurbiprofen administered at the site of tissue injury in the oral surgery model, 1419

Fluvoxamine
the differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers, 785
dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia, 1386
effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes, 1223

Food-drug interactions
effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 1380
a single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects, 173

Fosfluconazole
pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers, 284

Frovatriptan
pharmacokinetics of frovatriptan in adolescent migraineurs, 1158

FTY720
multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects, 532

Gamma hydroxybutyrate
pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients, 253

Garenoxacin
characterization of the penetration of garenoxacin into the breast milk of lactating women, 188

Gastric acid-related diseases
pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers, 73

GBD project
global burden of disease (GBD) for hepatitis C, 20

Gemtuzumab ozogamicin
pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia, 873

Genetic polymorphisms
differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms, 1083
genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers, 447

Geriatric volunteers
single-dose pharmacokinetics of daptomycin in young and geriatric volunteers, 612
utility of sparse concentration sampling for citalopram in elderly clinical trial subjects, 1353

Ginkgo biloba
the effects of *Ginkgo biloba* extracts on the pharmacokinetics and pharmacodynamics of donepezil, 538

Glucocorticoid therapy
MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration, 481

Glucocorticoids
pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients, 1003

Glucocorticosteroids
intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects of endogenous cortisol, 510

Glucose control
intense management of diabetes mellitus: role of glucose control and antiplatelet agents, 414
Glucose intolerance
preventing type II diabetes mellitus, 406
Glycoprotein IIb/IIIa
glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients, 1328
GnRH
pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75, 495
Haloperidol
intramuscular haloperidol or lorazepam and QT intervals in schizophrenia, 1173
Hand-foot syndrome
hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, 1166
Heparin
parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters, 474
Hepatic function
moderate liver impairment has no influence on daptomycin pharmacokinetics, 715
Hepatitis C
global burden of disease (GBD) for hepatitis C, 20
pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers, 265
Hepatocytes
induction of CYP3A4 be efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital, 1273
Herb-drug interactions
effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers, 95
Herbal medicine
the effects of *Ginkgo biloba* extracts on the pharmacokinetics and pharmacodynamics of donepezil, 538
Histamine H1-receptor (H1R)
central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H_1-receptor occupancy using ^{11}C-doxepin positron emission tomography, 890
HIV
indinavir and rifabutin drug interactions in healthy volunteers, 305
pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1–infected children, 1301
Hyperlipidemia
benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong, 632
clinical trials and lipid guidelines for type II diabetes, 423
Hypertension
blood pressure control and nephroprotection in diabetes, 431
optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240, 621
pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901
pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion, 503
pharmacological and clinical profile of moexipril: a concise review, 827
Ibandronate
ibandronate: a clinical pharmacological and pharmacokinetic update, 951
Ibuprofen
population pharmacokinetics of ibuprofen enantiomers in very premature neonates, 1114
Imatinib
absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion, 158
Indinavir
indinavir and rifabutin drug interactions in healthy volunteers, 305
Inhaled drugs
estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745, 348
Inhaled glucocorticoids
risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective, 37
Insulin detemir
similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy Caucasian and Japanese American subjects, 258
Interethnic variability
differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms, 1083
Interindividual variability
interindividual and intraindividual variability of the urinary 6β-hydroxycortisol/cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity, 1413
Intestinal absorption
quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl, 224
Irinotecan
influence of genetic variants in *UGT1A1* and *UGT1A9* on the in vivo glucuronidation of SN-38, 854
Itraconazole
renal interaction between itraconazole and cimetidine, 919
Juvenile rheumatoid arthritis
pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis, 866
Ketolide
pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment, 234
Kidney transplantation
pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients, 743
Kinetics
kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions, 605
Knee arthroplasty
efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty, 767
Lansoprazole
effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes, 1223
Leukemia
pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia, 873
population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia, 1309
Levofloxacin
measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings, 464
Levosimendan
pharmacokinetics and pharmacodynamics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study, 1143
Liver
moderate liver impairment has no influence on daptomycin pharmacokinetics, 715
serum metabolite/caffeine ratios as a test for liver function, 338
Lorazepam
intramuscular haloperidol or lorazepam and QT intervals in schizophrenia, 1173
Loteprednol etabonate
intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects of endogenous cortisol, 510
Lumiracoxib
concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile, 646
lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects, 193
Lupus erythematosus
interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays, 1034

Lymphocyte proliferation assays
interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays, 1034

Lymphocyte response
multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects, 532

M100240
effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 1380
no clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 379
pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901

Marijuana
effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [^{15}O]water: effect in occasional and chronic users, 751

Mass balance
estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745, 348

MDL 100,173
pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901

MDR1
tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, 135

Medicines
could the WHO model list of essential medicines do more for the safe and appropriate use of injections? 1106

Meloxicam
meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers, 777
pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis, 866

Menthol
dermal absorption of camphor, menthol, and methyl salicylate in humans, 1151

Metabolism
absorption of rivastigmine from different regions of the gastrointestinal tract in humans, 599

Metabolizers
genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers, 447
pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers, 1132

Methadone
the effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone, 293

Methods
assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH, 1399
estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745, 348
evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials, 457
global burden of disease (GBD) for hepatitis C, 20
limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers, 570
measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings, 464
serum metabolite/caffeine ratios as a test for liver function, 338

Methotrexate
unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid athritis, 1235

Methyl salicylate
dermal absorption of camphor, menthol, and methyl salicylate in humans, 1151

Methylprednisolone
pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients, 1003

Microgravity
physiological, pharmacokinetic, and pharmacodynamic changes in space, 837, pharmacokinetics, and pharmacodynamic changes in space, 837

Midazolam
evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity, 215
kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions, 605
no clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 379

Migraine
pharmacokinetics of frovatriptan in adolescent migraineurs, 1158
pharmacokinetics of sumatriptan nasal spray in children, 359

Modafinil
effect of modafinil on acute pain: a randomized double-blind crossover study, 1426

Molecular pharmacology
MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration, 481

Montelukast
pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old, 487

Morbidity
epidemiology of diabetes, 397

Movement disorders
single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers, 276

Movies
putting clinical pharmacology in context: the use of popular movies, 30

Multiple-daily dosing
application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing, 696

myocardial infarction
questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? 150

Mycophenolate mofetil
pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients, 743

N-acetylcystein
preventing contrast nephropathy: what is the best strategy? A review of the literature, 327

Nanobudesonide
the pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers, 67

Narcolepsy
pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients, 253

NAT1
metabolism by n-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition, 1406

Neonates
population pharmacokinetics of ibuprofen enantiomers in very premature neonates, 1114

NEP inhibition
effect of food on the pharmacokinetics of a dual angiotensin-coverting enzyme/neutral endopeptidase inhibitor, M100240, 1380
no clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 379
optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240, 621

Nephropathy
preventing contrast nephropathy: what is the best strategy? A review of the literature, 327

Neutral endopeptidase (NEP)
pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901

Nicotine
effects of nicotine on the number and activity of circulating endothelial progenitor cells, 881
NSAIDs
meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers, 777
Obesity
epidemiology of diabetes, 397
Olanzapine
the differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers, 785
dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia, 1386
Omeprazole
influence of azimilide on CYP2C19-mediated metabolism, 373
influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline, 640
lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping, 966
omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability, 582
randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate, 1392
OR-1855
pharmacokinetics and pharmacodynamics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study, 1143
OR-1896
pharmacokinetics and pharmacodynamics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study, 1143
Overdose
teaching application of clinical pharmacology skills using unusual observations from clozapine overdoses, 141
Oxcarbazepine
oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy, 1290
Oxymorphone
efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty, 767
P-glycoprotein
MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration, 481
quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl, 224
tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, 135
Pain
assessment of visual analog versus categorical scale for measurement of osteoarthritis pain, 368
effect of modafinil on acute pain: a randomized double-blind crossover study, 1426
efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty, 767
Pediatrics
characterization of the penetration of garenoxacin into the breast milk of lactating women, 188
comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children, 708
pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia, 873
pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis, 866
pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old, 487
pharmacokinetics of sumatriptan nasal spray in children, 359
population pharmacokinetics of ibuprofen enantiomers in very premature neonates, 1114
Percutaneous coronary intervention
pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention, 981
Pharmacoepidemiology
lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition, 861
Pharmacogenetics
differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms, 1083
influence of genetic variants in *UGT1A1* and *UGT1A9* on the in vivo glucuronidation of SN-38, 854
influence of St. John's wort on CYP2C19 activity with respect to genotype, 577
lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping, 966
omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability, 582
Pharmacokinetics and pharmacodynamics
absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers, 737
absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion, 158
absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion, 83
absorption of rivastigmine from different regions of the gastrointestinal tract in humans, 599
central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H_1-receptor occupancy using ^{11}C-doxepin positron emission tomography, 890
dermal absorption of camphor, menthol, and methyl salicylate in humans, 1151
DOV 216, 303, "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile, XXX
effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [^{15}O]water: effect in occasional and chronic users, 751
effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, 1380
effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes, 1223
the effects of *Ginkgo biloba* extracts on the pharmacokinetics and pharmacodynamics of donepezil, 538
efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty, 767
important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics, 1260
intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects of endogenous cortisol, 510
kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions, 605
lack of a clinically significant effect of zonisamide on phentyoin steady-state pharmacokinetics in patients with epilepsy, 1230
moderate liver impairment has no influence on daptomycin pharmacokinetics, 715
multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects, 532
optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240, 621
oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy, 1290
pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1–infected children, 1301
pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers, 73
pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers, 991
pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects, 520

pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients, 743

pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients, 1003

pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75, 495

pharmacokinetics and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study, 723

pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention, 981

pharmacokinetics and pharmacodynamics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study, 1143

pharmacokinetics and pharmacodynamics of the ET_A-selective endothelin receptor antagonist SPP301 in healthy human subjects, 59

pharmacokinetics and safety of fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers, 284

pharmacokinetics and safety of solifenacin succinate in healthy young men, 1023

pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers, 265

pharmacokinetics of articane hydrochloride in tumescent local anesthesia for liposuction, 1282

pharmacokinetics of etoricoxib in patients with renal impairment, 48

pharmacokinetics of frovatriptan in adolescent migraineurs in adolescent migrainueurs, 1158

pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment, 163

pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers, 901

the pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers, 67

pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers, 1252

pharmacokinetics, safety, and tolerability of R411, a dual α4β1-α4β7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers, 1369

pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients, 253

pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion, 503

pharmacokinetics, tolerability and safety of aripiprazole following multiple oral dosing in normal healthy volunteers, 179

pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment, 234

population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, 590

population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia, 1309

rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan, 245

risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective, 37

safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans, 906

sex-related differences in the pharmacokinetics of oral ciprofloxacin, 1012

similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy Caucasian and Japanese American subjects, 258

single-dose pharmacokinetics of daptomycin in young and geriatric volunteers, 612

a single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects, 173

single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers, 276

unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid athritis, 1235

Pharmacology

putting clinical pharmacology in context: the use of popular movies, 30

Phenobarbital

induction of CYP3A4 be efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital, 1273

Phenotyping

assessment of in vivo CYP2D6 activity: differential sensitivity on commonly used probes to urine pH, 1399

comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children, 708

Phenytoin

lack of a clinically significant effect of zonisamide on phentyoin steady-state pharmacokinetics in patients with epilepsy, 1230

Plasma

simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist, 680

Plasminogen activator inhibitor

questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? 150

Platelet GPIIB/IIIA receptor antagonists

pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention, 981

PNU-96391

single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers, 276

Polymorphism

tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, 135

Positron emission tomography (PET)

central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H_1-receptor occupancy using ^{11}C-doxepin positron emission tomography, 890

Prednisolone

interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays, 1034

Prevention

preventing type II diabetes mellitus, 406

Prostacyclin

pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion, 503

Proton pump inhibitors

pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers, 73

Psychomotor performance

central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H_1-receptor occupancy using ^{11}C-doxepin positron emission tomography, 890

Pulmicort respules

the pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers, 67

QT intervals

intramuscular haloperidol or lorazepam and QT intervals in schizophrenia, 1173

QTc interval prolongation

effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects, 689

Quinidine

pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers, 1132

quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl, 224

R411

pharmacokinetics, safety, and tolerability of R411, a dual α4β1-α4β7 integrin antagonist

after oral administration at single and multiple once-daily ascending doses in healthy volunteers, 1369

Racemate

role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus? 115

Radiocontrast-induced nephropathy

dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy, 1343

Randomized trials

clinical trials and lipid guidelines for type II diabetes, 423

Ranitidine

randomized crossover study investigating the influence of ranitidine or omeprazole on the pharmacokinetics of cephalexin monohydrate, 1392

Recombinant human erythropoietin

pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers, 991

Remodulin®

absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion, 83

pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion, 503

Renal failure

preventing contrast nephropathy: what is the best strategy? A review of the literature, 327

Renal impairment

pharmacokinetics of etoricoxib in patients with renal impairment, 48

pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment, 163

pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment, 234

Renal transplantation

pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients, 1003

Renal tubular secretion

renal interaction between itraconazole and cimetidine, 919

Research

evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials, 457

Rheumatoid arthritis

rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan, 245

unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid athritis, 1235

Ribavirin

pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers, 265

Rifabutin

indinavir and rifabutin drug interactions in healthy volunteers, 305

Rifampicin

influence of St. John's wort on CYP2C19 activity with respect to genotype, 577

Rifampin

induction of CYP3A4 be efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital, 1273

Ritonavir

the effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone, 293

lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients, 793

Rivastigmine

absorption of rivastigmine from different regions of the gastrointestinal tract in humans, 599

RO0270608

pharmacokinetics, safety, and tolerability of R411, a dual $\alpha4\beta1$-$\alpha4\beta7$ integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers, 1369

St. John's wort

effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers, 95

effects of St. John's wort (*Hypericum perforatum*) on tacrolimus pharmacokinetics in healthy volunteers, 89

influence of St. John's wort on CYP2C19 activity with respect to genotype, 577

Saquinavir

the effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone, 293

lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients, 793

Schizophrenia

dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia, 1386

intramuscular haloperidol or lorazepam and QT intervals in schizophrenia, 1173

Sex differences

sex-related differences in the pharmacokinetics of oral ciprofloxacin, 1012

Simvastatin

simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans, 1054

Skin infections

moderate liver impairment has no influence on daptomycin pharmacokinetics, 715

single-dose pharmacokinetics of daptomycin in young and geriatric volunteers, 612

Sleepiness

central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H_1-receptor occupancy using ^{11}C-doxepin positron emission tomography, 890

Smoking

lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers, 1046

SN-38

influence of genetic variants in *UGT1A1* and *UGT1A9* on the in vivo glucuronidation of SN-38, 854

Sodium

absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers, 737

parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters, 474

pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients, 253

pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion, 503

Solifenacin

pharmacokinetics and safety of solifenacin succinate in healthy young men, 1023

Space medicine

physiological, pharmacokinetic, and pharmacodynamic changes in space, 837

Sphingosine-1-phosphate receptor agonists

multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects, 532

SPP301

pharmacokinetics and pharmacodynamics of the ET_A-selective endothelin receptor antagonist SPP301 in healthy human subjects, 59

Stereoselective

role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus? 115

STI571

absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion, 158

Subcutaneous infusion

absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion, 83

Sumatriptan

pharmacokinetics of sumatriptan nasal spray in children, 359

Tacrolimus

effects of St. John's wort (*Hypericum perforatum*) on tacrolimus pharmacokinetics in healthy volunteers, 89

tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, 135

Tamoxifen

lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition, 861

Telavancin

effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects, 689

Telithromycin

pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment, 234

THC

effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [^{15}O]water: effect in occasional and chronic users, 751

Theophylline

effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers, 95

lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers, 1046

Thrombin inhibitor

no pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran, 928

no pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers, 935

a pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor, 1063

Thromboembolic disease

no pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran, 928

no pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers, 935

the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol, 388

Tiotropium

pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment, 163

Tolbutamide

evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity, 215

Tolerability

ibandronate: a clinical pharmacological and pharmacokinetic update, 951

pharmacokinetics and safety of solifenacin succinate in healthy young men, 1023

pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers, 265

single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers, 276

Toxicity

dermal absorption of camphor, menthol, and methyl salicylate in humans, 1151

Transplantation

effects of St. John's wort (*Hypericum perforatum*) on tacrolimus pharmacokinetics in healthy volunteers, 89

pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients, 743

tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism, 135

Treprostinil sodium

absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion, 83

Triphasil-28

concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile, 646

UGT1A1

influence of genetic variants in *UGT1A1* and *UGT1A9* on the in vivo glucuronidation of SN-38, 854

UGT1A9

influence of genetic variants in *UGT1A1* and *UGT1A9* on the in vivo glucuronidation of SN-38, 854

Uracile

important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics, 1260

Urine collection

comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children, 708

Urine pH

assessment of in vivo CYP2D6 activity: differential sensitivity on commonly used probes to urine pH, 1399

Valproate

absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers, 737

Valsartan

rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan, 245

Vasculogenesis

effects of nicotine on the number and activity of circulating endothelial progenitor cells, 881

Vasopeptidase inhibitor

optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240, 621

VCAM-1

pharmacokinetics, safety, and tolerability of R411, a dual $\alpha4\beta1$-$\alpha4\beta1$ integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers, 1369

Ventricular repolarization

measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings, 464

Vinorelbine

hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, 1166

Viramidine

pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers, 265

Visual analog

assessment of visual analog versus categorical scale for measurement of osteoarthritis pain, 368

VLA-4 antagonist

estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745, 348

Warfarin

absence of a pharmacokinetic interaction between etanercept and warfarin, 543

limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers, 570

World Health Organization (WHO)

could the WHO model list of essential medicines do more for the safe and appropriate use of injections? 1106

global burden of disease (GBD) for hepatitis C, 20

Ximelagatran

no pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran, 928

no pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers, 935

a pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor, 1063

the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol, 388

YH1885

pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers, 73

Zonisamide

lack of a clinically significant effect of zonisamide on phentyoin steady-state pharmacokinetics in patients with epilepsy, 1230